

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2A

CSF p217 + Tau
2step vs 3step




FIG. 2B

Serum p217 + Tau
2step vs 3step




FIG. 3A

Crude 3 Step
CSF (3.43) vs CSF (3.82)




FIG. 3B

Crude 3 Step
Serum (3.43) vs Serum (3.82)




FIG. 3C

Crude 3 Step
Plasma (3.43) vs Plasma (3.82)




FIG. 4A




FIG. 4B




FIG. 5A

Serum p217+Tau

Revised Assay: 02Dec2019





FIG. 5B

Plasma p217+Tau

Revised Assay: 02Dec2019



9/27

FIG. 5C

Plasma vs Serum





FIG. 5D

Plasma vs Serum



10/27

FIG. 6A

Calibrant Curves





FIG. 6B

Dilution Linearity

Run #3

Serum Crude



11/27

FIG. 7A




FIG. 7B




FIG. 7C




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D

ROC curve:
Plasma p217+Tau Dx Power for Predicting
CSF Tau Positivity
Cognitively Normal Subjects




FIG. 12E

CSF p217+Tau vs Plasma p217+Tau
Cognitively Normal Subjects




FIG. 12F

ROC curve:
Plasma p217+Tau Dx for Predicting
CSF Tau Positivity
Mild-moderate Dementia Subjects





FIG. 12G

CSF p217+Tau vs Plasma p217+Tau
Mild-moderate Dementia Subjects



19/27

FIG. 13A

ROC curve:
Plasma p217+Tau Dx for Predicting
CSF Amyloid Positivity
All Subjects





FIG. 13B

CSF A β 42/40 Ratio vs Plasma p217+Tau
All Subjects



20/27

FIG. 13C

ROC curve:
Plasma p217+Tau Dx Power for Predicting
CSF Amyloid Positivity
Cognitively Normal Subjects




FIG. 13D

CSF A β 42/40 Ratio vs Plasma p217
Cognitively Normal Subjects




FIG. 13E

ROC curve:
Plasma p217+Tau Dx Power for Predicting
CSF Amyloid Positivity
Mild-moderate Dementia Subjects




FIG. 13F

CSF A β 42/40 Ratio vs Plasma p217
Mild-moderate Dementia Subjects




FIG. 14A




FIG. 14B





FIG. 14C



Scatter plot showing p217 (pg/ml) for HV and AD groups. The y-axis ranges from 0.0 to 1.0. The HV group (n=15) has a mean of approximately 0.15 pg/ml. The AD group (n=15) has a mean of approximately 0.38 pg/ml. Individual data points are shown as black dots for HV and black squares for AD. Horizontal lines indicate the mean and standard deviation for each group.

FIG. 15B

FIG. 15C
Plasma TOTAL p217+Tau
Precision and Sensitivity




FIG. 16A
Serum Tau, AGE, SEX




FIG. 16B
Serum Tau, NFL, AGE, SEX




FIG. 16C

Serum Tau, NFL, Adiponectin, AGE, SEX




FIG. 16D

Serum Tau, NFL, Adiponectin, Leptin, AGE, SEX




FIG. 16E

Adiponectin, Leptin, NFL, AGE, SEX

